(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 March 2023 (16.03.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/039020 A1

(51) International Patent Classification:
A61K 31/33 (2006.01) *C07D 401/14* (2006.01)
A61K 31/395 (2006.01) *C07D 401/02* (2006.01)
C07D 401/06 (2006.01)

(21) International Application Number:
PCT/US2022/042835

(22) International Filing Date:
08 September 2022 (08.09.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/242,370 09 September 2021 (09.09.2021) US
63/357,600 30 June 2022 (30.06.2022) US

(71) Applicant: **MIRATI THERAPEUTICS, INC.** [US/US]; 3545 Cray Court, San Diego, CA 92121 (US).

(72) Inventors: **SCATTOLIN, Thomas**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121 (US). **CHEN, Cheng**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121 (US). **GHARBAOUI, Tawfik**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121 (US). **GAN, Yonghong**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121 (US). **ACHMATOWICZ, Michal**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121 (US). **SNEAD, David**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121 (US).

(74) Agent: **POLYAKOV, Mark, V.** et al.; Wood, Phillips, Katz, Clark & Mortimer, 500 West Madison Street, Suite 1130, Chicago, IL 60661 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2023/039020 A1

(54) Title: PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB

(57) Abstract: The present invention relates to improved synthetic routes of synthesizing adagrasib. The invention also provides intermediates used in the provided synthetic routes.